Amylin Analog Petrelintide Reduced Body Weight

Adults with overweight or obesity saw weight loss in a new trial of a once-weekly injectable.

Updated on Sept. 29, 2026 in Weight Loss

Isometric editorial illustration of arranged glass vials in deep teal and mustard, representing clinical research. — A Phase 2 clinical trial of the investigational drug petrelintide showed significant weight loss among participants after 42 weeks of treatment. AI Illustration. Upload story photo >

Live Poll

Would you consider using a new prescription medication for weight management if your doctor recommended it?

A Phase 2 clinical trial found that the investigational human amylin analog petrelintide led to significant body weight reductions. The findings from the study, which followed 485 participants for 42 weeks, could offer a new approach to chronic weight management.

Why it matters

As researchers seek additional options for obesity care, this drug aims to provide an alternative for weight reduction. Because petrelintide acts as an amylin analog, it represents a different mechanism for potentially supporting long-term weight management goals.

This Phase 2 trial of 485 adults evaluated petrelintide over 42 weeks, achieving a maximum mean weight reduction of 10.7% compared to placebo. While preliminary results are encouraging, long-term outcomes remain under investigation.

The players

Zealand Pharma

A pharmaceutical company based in Copenhagen that develops peptide-based medicines for metabolic and gastrointestinal conditions.

The details

Petrelintide functions as a human amylin analog, a hormone involved in regulating satiety and blood sugar. By mimicking this natural hormone, the once-weekly subcutaneous injection aims to influence metabolic processes to support weight loss. The trial recorded gastrointestinal side effects at rates similar to those seen in the placebo group.

Final body weight measurements for the trial were recorded at week 42.
Trial results are scheduled for presentation at EASD 2026 on September 30, 2026.

Diabetes
Sept. 29
Ozempic Dose Escalation Linked to Lower Heart Risk
Weight Loss
Sept. 22
Roche Enicepatide Trial Reduced Weight and HbA1c
Diabetes
Sept. 29
Experimental Obesity Drug Showed Early Potential

Health Landscape

The development of petrelintide signals a potential shift in obesity treatment by focusing on amylin signaling rather than established GLP-1 receptor agonist pathways. This trial adds to a growing pipeline of therapies designed to diversify the options available for long-term weight management.

These findings are strictly preliminary and do not change current medical advice or treatment plans for those managing weight. If you are exploring weight management options, speak with your doctor to discuss established, FDA-approved therapies appropriate for your specific health history.

The takeaway

This study demonstrates that a novel amylin analog can produce measurable weight loss with a manageable gastrointestinal side-effect profile. For those concerned about weight, tracking trends in metabolic health and consulting with a specialist about available evidence-based interventions remains the standard.

What happens next

Zealand Pharma is scheduled to present additional trial results at the EASD 2026 conference on September 30, 2026. The company also plans to launch a Phase 2 trial for a combination therapy during the second half of 2026.